<DOC>
	<DOCNO>NCT00605384</DOCNO>
	<brief_summary>The purpose clinical research study find whether combination entecavir ( ETV ) plus tenofovir ( TNF ) work well Hepatitis B virus adefovir ( ADV ) add continue lamivudine ( LVD ) therapy patient whose Hepatitis B virus ( HBV ) resistant lamivudine . The safety treatment also study .</brief_summary>
	<brief_title>A Phase IIIb Study Compare Entecavir Plus Tenofovir vs. Adefovir Added Continuing Lamivudine Therapy Adult Patients With Lamivudine-Resistant Hepatitis B Infection</brief_title>
	<detailed_description />
	<mesh_term>Hepatitis</mesh_term>
	<mesh_term>Hepatitis A</mesh_term>
	<mesh_term>Hepatitis , Chronic</mesh_term>
	<mesh_term>Hepatitis B</mesh_term>
	<mesh_term>Hepatitis B , Chronic</mesh_term>
	<mesh_term>Adefovir</mesh_term>
	<mesh_term>Adefovir dipivoxil</mesh_term>
	<mesh_term>Entecavir</mesh_term>
	<mesh_term>Lamivudine</mesh_term>
	<mesh_term>Tenofovir</mesh_term>
	<criteria>Chronic HBV infection History lamivudine ( LVD ) treatment , lamivudine resistance ( LVDr ) , receive LVD screen visit Compensated liver function HBV DNA â‰¥ 172,000 IU/mL Hepatitis B eantigen ( HBeAg ) positive HBeAgnegative Evidence decompensated cirrhosis Coinfection human immunodeficiency virus ( HIV ) , hepatitis C virus ( HCV ) , hepatitis D virus ( HDV ) Recent history pancreatitis Serum alpha fetoprotein &gt; 100 ng/mL Except lamivudine , prior therapy nucleoside nucleotide analogue antiviral agent activity hepatitis B</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2010</verification_date>
</DOC>